Arab Finance: Minapharm Pharmaceuticals has incurred standalone net losses after tax amounting to EGP 12.107 million during the first half (H1) of 2024, versus net profits of EGP 77.484 million in the same period last year, according to the financial statement filed to the Egyptian Exchange (EGX) on August 14th.
Sales amounted to EGP 1.313 billion in the first six months of 2024, up from EGP 1.251 billion in H1 2023.
Minapharm Pharmaceuticals is an Egypt-based company engaged in the production and distribution of pharmaceutical products. It is in cooperation with several international pharmaceutical companies and it distributes its products within and outside Egypt.